查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008683

阴道炎治疗市场：2026-2032年全球市场预测（依治疗方法、产品类型、给药途径、通路及最终用户细分市场划分）

Vaginitis Therapeutics Market by Treatment Type, Product Type, Route Of Administration, Distribution Channel, End User Demographics - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，阴道炎治疗市场价值将达到 30 亿美元，到 2026 年将成长至 32.6 亿美元，到 2032 年将达到 56.9 亿美元，复合年增长率为 9.55%。

主要市场统计数据
基准年 2025 30亿美元
预计年份：2026年 32.6亿美元
预测年份 2032 56.9亿美元
复合年增长率 (%) 9.55%

这是一份简洁而有力的阴道炎治疗概述，清楚地阐述了相关人员。

由于阴道炎涉及广泛的临床需求、诊断的复杂性以及不断变化的患者偏好，因此它一直是临床医生、保险公司和产品开发人员的焦点。以下引言概述了医疗保健和生命科学相关人员在製定产品组合决策、优先考虑临床开发以及製定商业化策略时应考虑的临床背景和策略因素。

透过科学突破、患者期望和医疗保健服务模式的改变，一股变革力量正在重塑阴道炎治疗的前景。

阴道炎治疗领域正经历着一场变革，这场变革是由科学、商业性和病患主导等多面向因素共同推动的。微生物组学和标靶抗真菌药物的科学进步正在拓展治疗选择，并使研发人员能够从通用产品转向针对特定病因和復发因素的干预措施。

本报告预测了 2025 年美国关税措施对阴道炎治疗的供应链、价格趋势和临床可及性的累积影响。

主要经济体实施的关税措施将对药品的采购、生产和分销产生连锁反应，预计美国将在2025年进行政策调整，这将要求阴道炎治疗的整个价值链进行周密的战略规划。进口关税的变化，无论是针对原料、成品或包装材料，都会影响采购决策、与供应商的谈判、生产基地的地理位置。为因应这种情况，企业应预估供应商集中度的变化，并考虑采用双重采购策略，以降低对单一国家供应商的依赖风险。

可操作的细分讯息，包括治疗领域、给药途径、产品类型、分销管道和人口统计群体，这些资讯可驱动临床和商业决策。

有效的细分对于阴道炎治疗的商业性和临床策略至关重要，因为它能明确临床差异和商业性机会的交会点。治疗方法区分了抗真菌疗法和益生菌疗法。在抗霉菌疗法中，又可分为Azole和Polyenes；Azole可细分为Clotrimazole、Fluconazole和Miconazole等主要药物，而Polyenes则包括Amphotericin B和製霉菌素。这种细分至关重要，因为不同类别药物的治疗方法、復发情况和抗药性均存在差异，从而影响临床动态和实证医学证据的需求。

美洲、欧洲、中东和非洲以及亚太地区的战略展望，决定市场进入和供应优先事项。

区域趋势对阴道炎治疗的整体情况产生显着影响，包括监管环境、供应链物流和病患就医策略。美洲地区拥有多元化的支付方体系和分销模式，公私采购机制并存，且数位化医疗的普及率稳步提升，因此，那些临床疗效显着且能遵守用药的产品更受青睐，而那些能够有效利用机构采购和零售/线上通路的製造商也将获得丰厚回报。

在不断发展的阴道炎治疗生态系统中，製造商、创新者和经销商面临的竞争力和业务挑战。

如今，阴道炎治疗市场的竞争优势取决于临床差异化、配方创新和分销弹性的综合运用。拥有丰富产品系列的成熟製造商通常利用规模经济来确保产品在销售管道的充足供应和快速补货，而规模小规模的创新型公司则通常在临床差异化、新型作用机製或更优的耐受性方面展开竞争。企业面临的策略挑战包括：投资于强有力的比较研究，以证明其产品能够降低復发率并显着改善病患报告结局（PRO）；以及开发有助于提高用药依从性和保护消费者隐私的包装和给药形式。

为阴道炎治疗产业的领导者提供极具影响力的策略建议，以改善患者治疗效果、优化产品组合併确保具有韧性的供应链。

产业领导者应在临床、商业和营运领域采取一系列以行动为导向、注重实施的步骤，将洞见转化为可衡量的成果。优先开发能够产生直接比较的临床结果和復发数据的途径至关重要，因为这些终点指标对支付者和临床医生的决策影响日益显着。临床计画必须辅以以病人为中心的证据，并利用这些证据来提案其价值，这些证据应涵盖用药依从性、生活品质 (QOL) 指标以及真实世界中的复发预防情况。

对稳健的调查方法进行概述，说明基础资料来源、分析架构、检验过程和治疗分析的限制。

本报告的研究基于三角测量法，该方法结合了对关键相关人员的访谈、对同行评审临床文献的系统性回顾、对监管指南的分析以及对分销和供应链指标的评估。主要资料来源包括对临床医生、处方集经理、采购经理和产品开发专家的结构化访谈，以获取关于临床需求、证据预期和获取挑战的第一手观点。次要分析整合了临床试验结果、指引更新和安全性概况，以确保临床结论是基于已发表的证据。

整合策略洞察和整体视角，将临床、监管和商业性知识转化为相关人员可采取的优先事项。

本报告的总结展望部分整合了临床、监管和商业性的见解，为参与阴道炎治疗的相关人员提出了一系列一致的优先事项。无论疗法的分类或给药途径如何，需求都很明确：能够显着降低復发率、提高耐受性和患者偏好的治疗方法最有可能获得持续推广。这需要一种综合方法，结合严谨的临床试验、真实世界数据 (RWE) 收集和数位化互动策略，以支持患者的用药依从性和监测。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法分類的阴道炎治疗市场

  • 抗真菌治疗
    • Azole
      • Clotrimazole
      • Fluconazole
      • Miconazole
    • Polyenes
      • Amphotericin B
      • 制霉菌素
  • 益生菌疗法

第九章 阴道炎治疗市场：依产品类型划分

  • 非处方药
  • 处方药

第十章 阴道炎治疗市场：依给药途径划分

  • 阴道内部
    • 奶油
    • 凝胶
    • 栓剂
  • 口服
    • 胶囊
    • 药片
  • 外用
    • 奶油
    • 凝胶
    • 软膏

第十一章 阴道炎治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：按最终用户细分的阴道炎治疗市场

  • 停经后妇女
    • 46-60岁
    • 60岁或以上
  • 闭经妇女
    • 18-25岁
    • 26-35岁
    • 36-45岁
  • 孕妇

第十三章 阴道炎治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 阴道炎治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 阴道炎治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国阴道炎治疗市场

第十七章：中国阴道炎治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer Aktiengesellschaft
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.
Product Code: MRR-8E22B61932BA

The Vaginitis Therapeutics Market was valued at USD 3.00 billion in 2025 and is projected to grow to USD 3.26 billion in 2026, with a CAGR of 9.55%, reaching USD 5.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.00 billion
Estimated Year [2026] USD 3.26 billion
Forecast Year [2032] USD 5.69 billion
CAGR (%) 9.55%

A concise yet compelling overview of vaginitis therapeutics that frames urgency, clinical unmet needs, and strategic priorities for stakeholders

Vaginitis remains a focal point for clinicians, payers, and product developers because it intersects prevalent clinical need, diagnostic complexity, and a shifting patient preference landscape. The introduction below frames the clinical context and strategic drivers that should inform portfolio decisions, clinical development prioritization, and commercialization strategies for stakeholders across healthcare and life sciences.

Clinically, vaginitis encompasses a spectrum of etiologies that demand divergent therapeutic approaches, ranging from antifungal regimens to probiotic adjuncts aimed at restoring microbiome balance. Diagnostic ambiguity persists in many care pathways, complicating treatment selection and driving patient dissatisfaction. At the same time, advancements in formulation science and increasing acceptance of at-home care pathways have expanded the tactical options available to manufacturers and providers. These trends create both opportunities for differentiated product positioning and risks for commoditization if clinical value is not clearly articulated.

From a strategic perspective, the convergence of regulatory scrutiny, payer emphasis on cost-effectiveness, and digital health enablement is reshaping how therapies progress from concept to clinic. Commercial strategies must therefore integrate clinical evidence generation, real-world outcomes capture, and patient-centric access models to build sustainable adoption. In short, the field calls for an integrated approach that aligns therapeutic innovation with pragmatic deployment in diverse care settings.

Evolutionary forces reshaping the vaginitis treatment landscape through scientific breakthroughs, patient expectations, and shifts in care delivery models

The landscape for vaginitis therapeutics is undergoing transformative shifts driven by converging scientific, commercial, and patient-driven forces. Scientific advances in microbiome science and targeted antifungal pharmacology are broadening the therapeutic toolkit, enabling developers to move beyond one-size-fits-all products toward interventions that address specific etiologies and recurrence drivers.

Concurrently, patients are exerting greater influence over care choices, favoring discreet, convenient, and evidence-backed options that fit into their daily routines. This has accelerated demand for oral and intravaginal formats that deliver rapid symptom relief while fitting home-based treatment paradigms. Digital diagnostics and telehealth are also reshaping early triage and treatment initiation, reducing barriers to care but raising expectations for integrated digital support and clear evidence of clinical benefit.

Commercial dynamics are evolving in parallel: payers and procurement stakeholders increasingly prioritize therapeutic value demonstrated through outcomes and reduced recurrence rates. Manufacturers that invest in robust post-market evidence, adherence support initiatives, and supply chain resilience will be better positioned to secure formulary access and provider endorsement. Taken together, these shifts signal a market that rewards targeted clinical differentiation, patient-centric delivery models, and data-driven value propositions.

Anticipating the cumulative implications of United States tariff actions in 2025 on supply chains, pricing dynamics, and clinical accessibility across vaginitis therapeutics

Tariff actions originating from major economies can have cascading effects across pharmaceutical sourcing, manufacturing, and distribution, and the United States policy adjustments anticipated in 2025 warrant careful strategic planning across the vaginitis therapeutics value chain. Changes in import duties, whether enacted on raw materials, finished dosage forms, or packaging components, can influence procurement decisions, supplier negotiations, and the geographic configuration of production footprints. In response, organizations should anticipate shifts in supplier concentration and consider dual-sourcing strategies to mitigate single-country exposure.

Price pressure may manifest differently across segments; products that are predominantly imported or rely on complex supply chains could see cost passthrough pressures that affect list prices, payer negotiations, and ultimately patient out-of-pocket costs. Moreover, tariff-induced cost variability can compress margins for commoditized therapeutics unless manufacturers proactively redesign supply chains, optimize formulation yields, or transition certain components to domestic production. Regulatory timelines and batch release processes must also be recalibrated when manufacturing relocations occur to prevent interruptions in product availability.

Beyond direct cost implications, tariffs can catalyze strategic responses such as increased vertical integration, regional manufacturing hubs, and greater emphasis on supplier partnerships that lock in long-term pricing and capacity. Stakeholders should therefore adopt scenario-based planning, stress-test procurement and distribution assumptions, and prioritize investments that enhance agility, cost visibility, and continuity of supply to reduce exposure to trade policy volatility.

Actionable segmentation intelligence on therapeutic classes, routes, product types, distribution channels, and demographic cohorts driving clinical and commercial decisions

Effective segmentation is foundational to commercial and clinical strategy in vaginitis therapeutics because it clarifies where clinical differentiation and commercial opportunities converge. Treatment type segmentation distinguishes antifungal therapies from probiotic approaches; within antifungal treatments there are class distinctions between azoles and polyenes, with azoles further segmented by dominant agents such as clotrimazole, fluconazole, and miconazole, while polyenes encompass amphotericin B and nystatin. This therapeutic granularity matters because pharmacodynamics, recurrence profiles, and resistance considerations differ across classes, shaping clinical positioning and evidence generation needs.

Route of administration is another pivotal segmentation axis. Intravaginal delivery subdivides into creams, gels, and suppositories, each offering distinct onset-of-action profiles, adherence implications, and patient preferences. Oral formulations are categorized into capsules and tablets, which present advantages in terms of systemic exposure and convenience but require different safety and labeling considerations. Topical preparations, including creams, gels, and ointments, serve unique roles in symptomatic relief and localized therapy and are evaluated differently by providers and patients.

Product type division between over-the-counter and prescription status impacts promotional approaches, regulatory obligations, and access pathways. Distribution channel segmentation spans hospital pharmacies, online pharmacies, and retail pharmacies, each with unique purchasing behaviors, formulary dynamics, and service expectations. Finally, end user demographic segmentation differentiates post-menopausal women, pre-menopausal women, and pregnant women; these cohorts are further stratified by age bands that influence prevalence, comorbidity profiles, and tolerability concerns. Integrating these segmentation dimensions enables stakeholders to design targeted clinical trials, tailor messaging to specific care settings, and prioritize channels that optimize adoption and adherence.

Regionally differentiated strategic outlooks for the Americas, Europe Middle East and Africa, and Asia-Pacific that inform market access and supply priorities

Regional dynamics exert a profound influence on regulatory pathways, supply logistics, and patient access strategies across the vaginitis therapeutics landscape. The Americas region combines diverse payer systems and distribution models, where private and public procurement mechanisms coexist and where digital care adoption is steadily increasing. These dynamics favor products that demonstrate a clear clinical differentiator or improved adherence, and they reward manufacturers that can navigate both institutional purchasing and retail/online channels.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways requires adaptive market entry playbooks. Some markets demand extensive clinical comparators and health economics evidence, while others prioritize cost-effective, easily deployable solutions. Supply chain complexity and variable cold chain infrastructures in certain geographies also influence product design and packaging decisions. In contrast, the Asia-Pacific region is characterized by rapid adoption of digital health platforms, high-volume demand for both prescription and over-the-counter solutions, and growing local manufacturing capacity. These attributes create opportunities for scalable, low-cost formulations as well as differentiated specialty products targeted at urban centers and digitally enabled patient segments.

Across all regions, local epidemiology, cultural perceptions of women's health, and access to primary care shape uptake. Consequently, regional strategies should align regulatory engagement, distribution partnerships, and patient education initiatives with local healthcare delivery realities to maximize clinical impact and commercial viability.

Competitive dynamics and corporate imperatives for manufacturers, innovators, and distributors competing in the evolving vaginitis therapeutics ecosystem

Competitive positioning in vaginitis therapeutics now hinges on a blend of clinical differentiation, formulation innovation, and distribution agility. Incumbent manufacturers that maintain broad product portfolios often leverage scale to secure channel placement and rapid replenishment, while smaller innovators typically compete on clinical differentiation, novel mechanisms, or superior tolerability profiles. Strategic imperatives for companies include investing in robust comparative evidence that demonstrates reduced recurrence and meaningful patient-reported outcomes, as well as developing packaging and delivery formats that enhance adherence and consumer discretion.

Collaboration between pharmaceutical developers and digital health firms has emerged as an important axis of competitive advantage, enabling bundled offerings that combine pharmacologic therapy with adherence support, symptom tracking, and remote clinician engagement. Moreover, companies that align product development with regulatory pathways for label expansion or OTC switches can unlock new access channels and broaden patient reach. Operationally, securing resilient manufacturing partnerships and flexible contract manufacturing agreements mitigates risk from supply interruptions and tariff-related cost shifts.

Mergers, licensing deals, and strategic alliances remain viable routes to accelerate capability acquisition, whether that entails gaining access to novel probiotic strains, advanced intravaginal delivery platforms, or regional distribution networks. Ultimately, successful companies will integrate clinical excellence with commercial finesse and operational resilience to navigate a competitive and policy-sensitive environment.

High-impact strategic recommendations for industry leaders to accelerate patient outcomes, optimize portfolios, and secure resilient supply chains in vaginitis care

Industry leaders should adopt a set of pragmatic, implementation-focused actions to translate insights into measurable outcomes across clinical, commercial, and operational domains. First, prioritize development pathways that generate head-to-head clinical outcomes and recurrence data, as these endpoints increasingly drive payer and clinician decision-making. Complement clinical programs with patient-centered evidence that captures adherence, quality-of-life metrics, and real-world recurrence prevention to strengthen value propositions.

Second, optimize product portfolios by aligning formulation choices with care settings and patient preferences; for example, invest in discreet intravaginal formats for home treatment, and ensure oral options are supported by clear safety profiles that enable wider primary care adoption. Third, build supply chain resilience through geographic diversification of manufacturing, strategic supplier contracting, and inventory strategies that accommodate tariff volatility and regional demand fluctuations. Fourth, accelerate digital integration by coupling therapies with telehealth-compatible diagnostics and adherence tools, thereby creating stickier patient journeys and enhancing clinical follow-up.

Finally, advance commercial readiness by tailoring distribution strategies across hospital pharmacies, retail points, and online pharmacies, and by developing payer engagement plans that foreground outcomes and economic case narratives. Executed together, these recommendations will help organizations convert scientific and commercial potential into durable clinical impact and market differentiation.

Robust research methodology overview describing data sources, analytical frameworks, validation processes, and limitations underpinning the therapeutic analysis

The research underpinning this report relies on a triangulated methodology that combines primary stakeholder interviews, systematic review of peer-reviewed clinical literature, analysis of regulatory guidelines, and evaluation of distribution and supply chain indicators. Primary inputs include structured interviews with clinicians, formulary managers, procurement leads, and product development experts to capture firsthand perspectives on clinical needs, evidence expectations, and access challenges. Secondary analyses synthesize clinical trial results, guideline updates, and safety profiles to ensure clinical assertions are grounded in the published evidence base.

Data on distribution practices and manufacturing configurations are derived from a combination of public regulatory filings, supply chain disclosures, and industry reports to map typical logistics flows and identify vulnerability points. Analytical frameworks incorporate scenario analysis to evaluate resilience under different trade and policy conditions, as well as cross-segmentation mapping to align product archetypes with distribution channels and end-user cohorts. Validation steps include peer review by subject-matter experts and consistency checks across independent data sources to minimize bias.

Limitations are acknowledged where primary data are constrained or where heterogeneity across regions inhibits universal conclusions. Where appropriate, recommendations are couched in conditional terms and accompanied by suggested next steps for further targeted evidence generation or in-market validation.

Synthesis of strategic insights and closing perspectives that translate clinical, regulatory, and commercial intelligence into executable priorities for stakeholders

The concluding perspective synthesizes clinical, regulatory, and commercial insights into a coherent set of priorities for stakeholders invested in vaginitis therapeutics. Across therapeutic classes and routes of administration, the imperative is clear: therapies that demonstrate meaningful reductions in recurrence, improved tolerability, and alignment with patient preferences are most likely to achieve durable adoption. Implementing this requires an integrated approach that pairs rigorous clinical programs with real-world evidence collection and digital engagement strategies to support adherence and monitoring.

Operational resilience is equally essential; organizations must address supply chain fragility and tariff exposure through diversified sourcing, regional manufacturing options, and strategic inventory management. Commercially, segmentation-informed go-to-market strategies that consider route of administration, product type, distribution channel, and end-user demographics will sharpen targeting and reduce commercial waste. Finally, collaboration across industry, clinical societies, and payer stakeholders can accelerate development of standardized diagnostics and care pathways that benefit patients and streamline adoption.

Taken together, these priorities form a roadmap for translating scientific advances into tangible improvements in patient outcomes while preserving commercial viability in a complex and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaginitis Therapeutics Market, by Treatment Type

  • 8.1. Antifungal Treatments
    • 8.1.1. Azoles
      • 8.1.1.1. Clotrimazole
      • 8.1.1.2. Fluconazole
      • 8.1.1.3. Miconazole
    • 8.1.2. Polyenes
      • 8.1.2.1. Amphotericin B
      • 8.1.2.2. Nystatin
  • 8.2. Probiotic Treatments

9. Vaginitis Therapeutics Market, by Product Type

  • 9.1. Over The Counter
  • 9.2. Prescription

10. Vaginitis Therapeutics Market, by Route Of Administration

  • 10.1. Intravaginal
    • 10.1.1. Creams
    • 10.1.2. Gels
    • 10.1.3. Suppositories
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Tablets
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Gels
    • 10.3.3. Ointments

11. Vaginitis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Vaginitis Therapeutics Market, by End User Demographics

  • 12.1. Post-Menopausal Women
    • 12.1.1. Age 46-60
    • 12.1.2. Age 60+
  • 12.2. Pre-Menopausal Women
    • 12.2.1. Age 18-25
    • 12.2.2. Age 26-35
    • 12.2.3. Age 36-45
  • 12.3. Pregnant Women

13. Vaginitis Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vaginitis Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vaginitis Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vaginitis Therapeutics Market

17. China Vaginitis Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer Aktiengesellschaft
  • 18.6. Cipla Limited
  • 18.7. Dr. Reddy's Laboratories Ltd.
  • 18.8. Glenmark Pharmaceuticals Ltd.
  • 18.9. Lupin Limited
  • 18.10. Pfizer Inc.
  • 18.11. Sun Pharmaceutical Industries Limited
  • 18.12. Teva Pharmaceutical Industries Ltd.
  • 18.13. The Procter & Gamble Company
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 242. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 247. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 251. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 255. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 284. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 293. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 294. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 297. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 298. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 303. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 306. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 307. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 308. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 311. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DE